NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
Clinical Trials
10 trialsNCT01253668 2021-04-13
Brivanib Metastatic Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT01118351 2019-05-01
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00466752 2017-11-22
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
University of Washington
Phase 2 Completed
NCT00717587 2014-01-10
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01118039 2013-08-07
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01158534 2012-08-07
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01340599 2012-03-15
Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00176527 2009-12-11
Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00323791 2009-12-11
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated